1. Home
  2. LBRX vs IGR Comparison

LBRX vs IGR Comparison

Compare LBRX & IGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LBRX

LB Pharmaceuticals Inc

N/A

Current Price

$25.69

Market Cap

602.6M

Sector

Health Care

ML Signal

N/A

Logo CBRE Global Real Estate Income Fund of Beneficial Interest

IGR

CBRE Global Real Estate Income Fund of Beneficial Interest

HOLD

Current Price

$4.43

Market Cap

645.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
LBRX
IGR
Founded
2015
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
602.6M
645.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LBRX
IGR
Price
$25.69
$4.43
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$50.67
N/A
AVG Volume (30 Days)
209.4K
702.6K
Earning Date
05-09-2026
01-01-0001
Dividend Yield
N/A
13.93%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.40
$4.15
52 Week High
$27.55
$5.37

Technical Indicators

Market Signals
Indicator
LBRX
IGR
Relative Strength Index (RSI) 59.48 44.46
Support Level $22.39 $4.20
Resistance Level $27.55 $5.04
Average True Range (ATR) 1.49 0.10
MACD 0.06 0.00
Stochastic Oscillator 63.31 50.91

Price Performance

Historical Comparison
LBRX
IGR

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.

About IGR CBRE Global Real Estate Income Fund of Beneficial Interest

CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.

Share on Social Networks: